No abstract available.
Colitis ; Humans ; Immunosuppressive Agents

No abstract available.
Herpes Zoster* ; Humans ; Immunosuppressive Agents*

Study on white mices with age of 6-8 weeks, 18-20g body weight. They were divided into 3 groups: group 1 (control group): 30 mices; group 2: mices were immunesuppressed by 200mg cyclophosphamid per one kilogram of body weight, being checked after 5 days of injection; and 300mg cyclophosphamid per one kilogram (200mg on the first day and 100mg on the fifth day) and it was checked after 10 days of injection (group 3). The results: immunesuppressed model implemented by intraperitonial injection of 200mg per one kilogram of body weight checked after 5 days of injeciton. These parameters were used to assign the immune function
Immunosuppressive Agents ; Mice ; Animal Experimentation ; Cyclophosphamide

No abstract available.
Cyclosporine ; Humans ; Immunosuppressive Agents* ; Psoriasis* ; Sarcoma, Kaposi*

No abstract available.
Cyclosporine ; Humans ; Immunosuppressive Agents* ; Psoriasis* ; Sarcoma, Kaposi*

No abstract available.
Adult* ; Humans ; Immunosuppressive Agents* ; Nephrotic Syndrome*

Tacrolimus (FK506) is a 23-membered macrolide with immunosuppressant activity that is widely used clinically for treating the rejection after organ transplantation. The research on tacrolimus production was mainly focused on biosynthesis methods, within which there are still some bottlenecks. This review summarizes the progress made in tacrolimus biosynthesis via modification of metabolic pathways and control of fermentation process, with the hope to address the technical bottlenecks for tacrolimus biosynthesis and improve tacrolimus production by fermentation engineering and metabolic engineering.
Tacrolimus ; Immunosuppressive Agents ; Fermentation ; Macrolides ; Anti-Bacterial Agents

Kaposi's sarcoma (KS) is a multifocal, systemic tumor of an endothelial cell origin and there are four clinical subtypes. Among these clinical subtypes, KS associated with immunosuppressive therapy mainly develops in organ transplant patients as well as in other patients who are receiving immunosuppressants for other reasons. It can occur from 1 month to more than 10 years after starting the agent and it seems to depend on the dose and type of the drug taken. We report here on a case of diffuse cutaneous iatrogenic Kaposi's sarcoma that was associated with 2 years of oral corticosteroid therapy. The patient's disease was present as various forms of cutaneous lesions without any systemic involvement.
Endothelial Cells ; Humans ; Immunosuppressive Agents ; Sarcoma, Kaposi ; Transplants

Drug Monitoring ; Humans ; Immunosuppressive Agents ; administration & dosage ; Liver Transplantation ; methods

Cytomegalovirus (CMV) infections commonly develop between the second and sixth month after renal transplantation. The incidence of CMV infection in renal transplant recipients, which depends on their serological status regarding CMV antibody and the use of immunosuppressants, is reported to be 38~67%. However, CMV infection after renal transplantation has been rarely reported in Korea. Recently, we experienced 4 cases of symptomatic CMV infection after renal transplantation, which were diagnosed by CMV antigenemia assay. With the development of more sensitive diagnostic methods, CMV infection may become recognized more commonly among renal transplant recipients.
Cytomegalovirus Infections* ; Cytomegalovirus* ; Immunosuppressive Agents ; Incidence ; Kidney Transplantation* ; Korea ; Transplantation